Bottom line
XBI vs FBDIX: the short answer
XBI (State Street(R) SPDR(R) S&P(R) Biotech ETF) and FBDIX (Franklin Biotechnology Discovery Fund) are quite different portfolios: only about 18% of their top holdings (by weight) are shared.
XBI is cheaper at 0.35% vs 1.01% — a difference of $66 a year per $10,000 invested.
Over five years, FBDIX returned +5.0% a year vs −2.7% for XBI.
FBDIX has a front-end sales load of up to 5.5%; the other does not.
Updated Nov 19, 2026
XBI vs FBDIX side by side
| XBI | FBDIX | |
|---|---|---|
| Type | ETF | Mutual fund |
| Fund family | SPDR (State Street) | Franklin Templeton |
| Category | Technology Sector | Technology Sector |
| Expense ratio | 0.35% | 1.01% |
| Annual cost per $10k | $35 | $101 |
| 10-yr cost on $10k (prospectus) | $443 | $1,728 |
| Max front load | None | 5.5% |
| 12b-1 fee | 0% | 0.25% |
| 1-yr return | +35.8% | +43.9% |
| 5-yr return (annualized) | −2.7% | +5.0% |
| 10-yr return (annualized) | +5.8% | +6.4% |
| Best quarter | +44.4% | +29.5% |
| Worst quarter | −26.2% | −24.5% |
| Net assets (fund) | $10.7B | $1.2B |
| Number of holdings | 161 | 126 |
| Portfolio turnover | 71% | 38% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | XBI | FBDIX | Difference |
|---|---|---|---|
| 2025 | +35.8% | +52.3% | −16.5% |
| 2024 | +1.1% | +4.0% | −2.9% |
| 2023 | +7.5% | +18.4% | −10.9% |
| 2022 | −25.8% | −12.7% | −13.1% |
| 2021 | −20.5% | −17.7% | −2.8% |
| 2020 | +48.2% | +29.9% | +18.3% |
| 2019 | +32.2% | +34.8% | −2.6% |
| 2018 | −14.9% | −15.7% | +0.8% |
| 2017 | +43.7% | +18.8% | +24.9% |
| 2016 | −15.4% | −17.2% | +1.7% |
Source: Fund prospectus bar charts
Holdings overlap
6 of XBI's top 25 holdings also appear in FBDIX's top 25.
| Holding | XBI | FBDIX |
|---|---|---|
| Oruka Therapeutics Inc | 1.38% | 1.86% |
| Praxis Precision Medicines Inc | 1.29% | 1.91% |
| Revolution Medicines Inc | 1.20% | 3.01% |
| Dianthus Therapeutics Inc | 1.18% | 2.32% |
| Cytokinetics Inc | 1.18% | 1.24% |
| Mirum Pharmaceuticals Inc | 1.16% | 1.98% |
Source: SEC Form N-PORT
XBI top 10
- State Street Global Advisors — 5.87%
- Apogee Therapeutics Inc — 1.49%
- Moderna Inc — 1.41%
- Twist Bioscience Corp — 1.41%
- Oruka Therapeutics Inc — 1.38%
- Kymera Therapeutics Inc — 1.36%
- Viking Therapeutics Inc — 1.30%
- Praxis Precision Medicines Inc — 1.29%
- Erasca Inc — 1.27%
- Revolution Medicines Inc — 1.20%
FBDIX top 10
- Jazz Pharmaceuticals plc — 5.66%
- Amgen, Inc. — 4.39%
- Gilead Sciences, Inc. — 3.86%
- Regeneron Pharmaceuticals, Inc. — 3.77%
- Argenx SE — 3.62%
- Vertex Pharmaceuticals, Inc. — 3.54%
- Franklin Institutional U.S. Government Money Market Fund — 3.18%
- Revolution Medicines, Inc. — 3.01%
- Guardant Health, Inc. — 2.76%
- Ascendis Pharma A/S — 2.56%
FAQ
What is the difference between XBI and FBDIX?
Which is cheaper, XBI or FBDIX?
Should I own both XBI and FBDIX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.